This meta-analysis assesses whether use of sodium-glucose cotransporter 2 inhibitors (SFLT2-Is) is associated with cardiovascular benefits in patients with atherosclerotic cardiovascular disease or its risk factors, diabetes, or heart failure. Here, SLC5A2 is linked to heart failure.